Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04598009
Title Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant Melanoma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors University of California, San Francisco
Indications

melanoma

Therapies

Binimetinib + Imatinib

Age Groups: adult | senior
Covered Countries USA

Additional content available in CKB BOOST